Product Approvals In Brief: Xalkori Gets Full Approval, H5N1 Flu Vaccine Approved
Pfizer gains full approval for its lung cancer treatment Xalkori, following accelerated approval in 2011; also updates on ID Biomedical’s adjuvanted H5N1 flu vaccine; a new indication for Bayer/Onyx’s cancer treatment Nexavar; a new formulation for Merck’s antifungal Noxafil; and BTG’s new varicose vein product Varithena.
You may also be interested in...
The addition of Onyx’s cancer drugs to Amgen’s portfolio will fill a near-term sales gap for the big biotech and reinforce the company as a major oncology player. But Amgen will need to execute expertly on the merger if it is to transform itself into a high-growth biotech.
Pfizer says that it won’t challenge NICE’s final rejection of Xalkori on cost-effectiveness and survival uncertainty grounds.
Principal Deputy Commissioner Woodcock is overseeing an enterprise-wide technology campaign intended to improve access to agency information and data.